Skip to main content

Newsroom

Latest News

January 10, 2022

WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO) released the following statement on U.S. Rep. Ed Perlmutter's (D-CO) announcement today that he will retire at the end of his term:

January 6, 2022

WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO) released the following statement today on the anniversary of the January 6, 2021 attack on the U.S. Capitol building:

December 13, 2021

WASHINGTON, D.C. – All six Democratic members of Colorado's congressional delegation today sent a letter – led by U.S. Rep. Diana DeGette (D-CO) – calling on the U.S.

December 10, 2021

WASHINGTON, D.C. – The co-chairs of the congressional Pro-Choice Caucus, U.S. Reps. Diana DeGette (D-CO) and Barbara Lee (D-CA), released the following statement today in response to the U.S. Supreme Court's decision to allow Texas's six-week abortion ban to remain in effect:

December 1, 2021

WASHINGTON, D.C. – U.S. Reps. Diana DeGette (D-CO), Frank Pallone, Jr. (D-NJ), Cathy McMorris Rodgers (R-WA) and Morgan Griffith (R-VA) sent a letter today to the U.S.

December 1, 2021

WASHINGTON, D.C.— The co-chairs of the Congressional Pro-Choice Caucus, U.S. Reps.

November 19, 2021

Reps. Diana DeGette (D-Colo.) and Fred Upton (R-Mich.) introduced the Cures 2.0 Act (H.R. 6000) on Nov. 15, a bill aimed at accelerating medical research and patient access to novel therapeutics.

November 19, 2021

WASHINGTON, D.C. – The U.S. House of Representatives today approved a once-in-a-generation spending bill that seeks to make health care, child care, housing and education more affordable for millions of hardworking families, and take on the global climate crisis.

November 18, 2021

WASHINGTON, D.C. – The co-chairs of the Congressional Diabetes Caucus, U.S. Reps.

November 16, 2021

WASHINGTON, D.C. –U.S. Reps. Diana DeGette (D-CO) and Fred Upton (R-MI) today introduced their highly anticipated, bipartisan Cures 2.0 legislation that some leading health care organizations are calling a potential "game changer" in how the U.S. conducts biomedical research going forward.